Tolvaptan drug tested in healthy men for safety and body processing
NCT ID NCT07166887
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 trial tested the drug tolvaptan (7.5mg) in 12 healthy men to see how the body absorbs, processes, and eliminates it. Participants took the tablet eight times over nine days. The study measured drug levels in the blood and checked for side effects, but it was not designed to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tolvaptan
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer reveals the Body's journey of an experimental drug
- Can music lessons rewire Teens' social media habits?
- Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Sound waves as medicine: ultrasound may tame inflammation without drugs
- Broader pneumonia shield: new vaccine tested in children